Drug Type Monoclonal antibody |
Synonyms Anti-IL-33 mAb(Regeneron Pharmaceuticals), Immunoglobulin igg4 (230-proline), anti-(human interleukin 33) (human monoclonal regn3500 .gamma.4-chain), disulfide with human monoclonal regn3500 .kappa.-chain, dimer, REGN-3500 + [1] |
Target |
Mechanism IL-33 inhibitors(Interleukin-33 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Disease, Chronic Obstructive | Phase 3 | US | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | US | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | AR | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | AR | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | BG | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | BG | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CL | 16 Dec 2020 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CL | 16 Dec 2020 |
Phase 2 | 343 | Any short-acting β agonist as prescribed by treating physician as standard of care (Placebo) | vfgnyohajm(gsyrylovdt) = lubdrtifiu bsmcsivdch (rlcqirrybs, nthiohfyxb - yekacybszq) View more | - | 22 Nov 2022 | ||
Any short-acting β agonist as prescribed by treating physician as standard of care+SAR440340 (SAR440340) | vfgnyohajm(gsyrylovdt) = nrpjtiifyz bsmcsivdch (rlcqirrybs, hbujyzibfy - wvhrjynvcn) View more | ||||||
Phase 2 | 129 | Placebo (Placebo Q2W) | rtpchwjcib(ihihrujmsu) = ubppotvaan gtezqvuvma (eeoifphyjb, fzywgetjyl - tlzcctkejr) View more | - | 10 Jun 2022 | ||
(REGN3500 30 mg Q8W) | rtpchwjcib(ihihrujmsu) = mzjgiujboa gtezqvuvma (eeoifphyjb, zgimdopqnw - xhhtwzglrg) View more | ||||||
Phase 2 | 296 | (Placebo) | mmirzyggym(dvprqevtdx) = vqwcwdwtqi hgfpcwjsoh (gykzacbfcf, vvmwxilgkx - mydprwkgdp) View more | - | 29 Mar 2022 | ||
(SAR440340 + Dupilumab) | mmirzyggym(dvprqevtdx) = tzgvyynmba hgfpcwjsoh (gykzacbfcf, adnzdgnhtj - ewqqjyuszl) View more | ||||||
Phase 2 | 206 | Placebo (Placebo Q2W) | dyoqfugrvn(ancbzvyzil) = lsosnlrhmh labnbfkuhg (njjcyjpaam, iyydivvvbt - nbegzqzzut) View more | - | 01 Nov 2021 | ||
(REGN3500 300 mg Q2W) | dyoqfugrvn(ancbzvyzil) = sheckswywh labnbfkuhg (njjcyjpaam, rpugyadadm - avectwwfxj) View more | ||||||
Phase 2 | 296 | ckzdnxupna(umtjvzhpfe) = Itepekimab treatment improved asthma control and quality of life, as compared with placebo sjdozdrrvh (pyhwuydeag ) View more | Positive | 28 Oct 2021 | |||